Publications by authors named "Penny Fleck"

Claim this Profile
P
Phase 1/2 AAV5-hRKp.RPGR (Botaretigene Sparoparvovec) Gene Therapy: Safety and Efficacy in RPGR-Associated X-Linked Retinitis Pigmentosa.
Michel Michaelides, Cagri G Besirli, Yesa Yang, Thales A C DE Guimaraes, Sui Chien Wong, Penny R Fleck

Am J Ophthalmol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Gene Therapy Trial of AAV8-hCARp.hCNGB3 in Adults and Children With CNGB3-associated Achromatopsia.
Michel Michaelides, Nashila Hirji, Sui Chien Wong, Cagri G Besirli, Serena Zaman, Penny Fleck

Am J Ophthalmol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose-ranging study.
Nicholas A Di Prospero, Jaqueline Yee, Mary E Frustaci, Mahesh N Samtani, Maria Alba, Penny Fleck

Clin Obes· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study.
Maria Alba, Jaqueline Yee, Mary Ellen Frustaci, Mahesh N Samtani, Penny Fleck

Clin Obes· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial.
William B White, Stuart Kupfer, Faiez Zannad, Cyrus R Mehta, Craig A Wilson, Penny R Fleck

Diabetes Care· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Faiez Zannad, Christopher P Cannon, William C Cushman, George L Bakris, Venu Menon, Penny R Fleck

Lancet· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Post Hoc Analysis of HbA1c, Hypoglycemia, and Weight Change Outcomes with Alogliptin vs Glipizide in Older Patients with Type 2 Diabetes.
Morgan Bron, Craig Wilson, Penny Fleck

Diabetes Ther· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes.
Daniël H Van Raalte, Renate E van Genugten, Björn Eliasson, Diane L Möller-Goede, Andrea Mari, Penny Fleck

Eur J Endocrinol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, Penny R Fleck

N Engl J Med· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
William B White, George L Bakris, Richard M Bergenstal, Christopher P Cannon, William C Cushman, Penny Fleck

Am Heart J· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes.
Julio Rosenstock, Silvio E Inzucchi, Jochen Seufert, Penny R Fleck, Craig A Wilson

Diabetes Care· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.
Richard E Pratley, Thérèse McCall, Penny R Fleck, Craig A Wilson, Qais Mekki

J Am Geriatr Soc· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.
Aziz Karim, Aziz Laurent, Melvin Munsaka, Elisabeth Wann, Penny Fleck

J Clin Pharmacol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Richard E Pratley, Jane E -B Reusch, Penny R Fleck, Craig A Wilson, Qais Mekki

Curr Med Res Opin· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.
Ralph A DeFronzo, Penny R Fleck, Craig A Wilson, Qais Mekki,

Diabetes Care· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
Paul Covington, Ronald Christopher, Michael Davenport, Penny Fleck, Qais A Mekki

Clin Ther· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
Ronald Christopher, Paul Covington, Michael Davenport, Penny Fleck, Qais A Mekki

Clin Ther· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy.
Paulos Berhanu, Mark S Kipnes, Mehmood A Khan, Alfonso T Perez, Stuart F Kupfer, Penny R Fleck

Diab Vasc Dis Res· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis